Accustem Sciences Inc (ACUT) USD0.001
![](https://online.hl.co.uk/img/hl/layout/security-nochange-arrow.gif)
- Add to watchlist
- This stock can be held in a
![](https://online.hl.co.uk/img/hl/layout/security-nochange-arrow.gif)
Business summary
AccuStem Sciences, Inc. is a clinical-stage diagnostics company. The Company is focused on developing and commercializing a suite of genomic tests that support decision-making along the entire continuum of oncology care. The Company's product candidate is StemPrintER, a 20-gene prognostic assay intended to predict the risk of distant recurrence (DR) in luminal (ER+/HER2-negative) breast cancer patients. In addition, the Company is focused on offering ancillary commodity testing (hereditary genetic testing, somatic mutation testing) that augments its assays and provides additional information to patients and physicians throughout the patient care continuum. The Company also holds licensing rights for the MicroRNA Signature Classifier (MSC) test, which is designed to help determine whether lung nodules identified by low-dose computed tomography (LDCT) screening are benign or malignant. The Company's wholly owned subsidiary is StemPrintER Sciences Limited.
Contact details
Important dates
General stock information
- Short code:
- ACUT
- ISIN:
- US00444A1016
- Market cap:
- $5.80 million
- Shares in issue:
- 11.35 million
- Sector:
- Biotechnology
- Exchange:
- Off Exchange
- Country:
- United States
- Currency:
- US dollar
- Indices:
- n/a
Key personnel
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.